[Modified vascular endothelia growth factor receptor-mediated targeting nonviral gene delivery system and in vivo beta-gal transducing experiment].
To investigate whether the modified vascular endothelial growth factor (VEGF) receptor-mediated targeting nonviral gene delivery system is efficient in transducing exogenous gene. We detected the expression of VEGF receptor on some tumor models by immunohistochemistry at first and selected nine models, i.e. SMMC-7721, SK-OV-3, H128, SPC-A1, LoVo, MKN-45, BCaP-37, A375, cervical cancer xenograft and hepatoma xenograft. Then we prepared two complexes, GV1-P.L./beta-gal and GV2-P.L./beta-gal, and injected the two complexes subcutaneously into nude mice around the tumor. The expression of the reporter gene was observed in the vascular endothelial cells and some tumor cells with highly expressed VEGF receptor. GV2 gene delivery system could transduce exogenous gene into vascular endothelial cells and subcutaneously transplanted tumors such as SK-OV-3, and cervical xenograft which were rich of VEGF receptor on the surface of the tumor cell. The expression reached a high level at day 3 and decreased eventually until the 3(rd) week. There was no expression in the heart and lung but low expression was seen in the spleen. GV1 gene delivery system also transduced exogenous gene into the endothelial cells but with low efficiency. This system can specifically transduce beta-gal to cells rich of VEGF receptor but not to cells with undetectable VEGF receptor. The targetability of this modified system is increased as compared to the system previously reported.